ARTICLE | Company News
Connetics, Flamel deal
January 8, 2001 8:00 AM UTC
FLMLY will conduct feasibility testing of CNCT's Relaxin recombinant human relaxin-H2 formulated using FLMLY's Medusa controlled release delivery technology. Relaxin is intended to treat cardiovascul...